Iparomlimab and Tuvonralimab before surgery for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests two drugs given before surgery to people with liver cancer that has a high chance of coming back. The goal is to see if the drugs can shrink the tumor and lower the risk of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have liver cancer that has not spread to other parts of your body.
- Your liver cancer can be surgically removed and has high risk of returning (for example, at least 2 tumors or tumor invasion into small branches of the portal vein).
- You have not received any prior cancer medication for liver cancer.
- Your blood tests show adequate liver, kidney, and bone marrow function (examples: platelets above 75, hemoglobin above 9.0, total bilirubin less than 2 times the upper normal limit).
- You are willing to use effective birth control during treatment and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines two immunotherapy drugs with a targeted therapy, radiation, and a liver-directed chemotherapy infusion for liver cancer that has spread to the portal vein (the main blood vessel to the liver). The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests whether giving an immunotherapy drug called QL1706 before surgery can help lower the risk of liver cancer coming back. It is for people with early-stage liver cancer that is at higher risk of returning, and the goal is to see if this approach is safe and effective.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus lenvatinib (a targeted therapy) given before surgery for hepatocellular carcinoma (a type of liver cancer). The goal is to see if this treatment can shrink tumors and reduce the chance of cancer coming back after surgery.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus bevacizumab (a drug that cuts off blood supply to the tumor) given after surgery or ablation for liver cancer. The goal is to lower the chance of cancer coming back. The treatment is given as an infusion and may help patients with certain high-risk features.
This trial tests a combination of immunotherapy drugs, radiation therapy, and a targeted therapy drug before and after surgery for people with intermediate-stage liver cancer that can be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests two immunotherapy drugs (Tuvonralimab and Iparomlimab) given before surgery to shrink bile duct cancers that are borderline removable. The goal is to make the tumor easier to remove completely and improve outcomes.
Hear when a new Resectable Hepatocellular Carcinoma With High Risk of Recurrence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.